

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number  
**WO 2005/004607 A1**

(51) International Patent Classification<sup>7</sup>: A01N 43/58,  
43/60, 43/42, 43/40, 43/64, 43/52, A61K 31/495, 31/50,  
31/44, 31/41, 31/415

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/US2004/020062

(22) International Filing Date: 25 June 2004 (25.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/484,220 2 July 2003 (02.07.2003) US  
10/875,507 25 June 2004 (25.06.2004) US

(71) Applicant (for all designated States except US): SUGEN,  
INC. [US/US]; 230 East Grand Avenue, South San Fran-  
cisco, CA 94808 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CUI, Jingrong  
[US/US]; 13718 Treviso Court, San Diego, CA 92130  
(US). BOTROUS, Iriny [US/US]; 11120 Scripps Ranch  
Blvd., #8, San Diego, CA 92131 (US).

(74) Agents: BURROUS, Beth A. et al.; Foley & Lardner LLP,  
Washington Harbour, 3000 K Street, NW, Suite 500, Wash-  
ington, DC 20007-5101 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,  
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG)


— as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations

Published:


— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.


(54) Title: ARYLMETHYL TRIAZOLO AND IMIDAZOPYRAZINES AS C-MET INHIBITORS




(I)



(II)



(III)







(IV)

(57) Abstract: The present invention relates to compounds of the Formulae (I) - (IV), wherein R<sub>1</sub> - R<sub>6</sub>, R<sub>11</sub> - R<sub>13</sub>, X and Y are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.

WO 2005/004607 A1

## ABSTRACT

The present invention relates to compounds of the Formulae (I) – (IV), wherein  $R_1$ ,  $R_6$ ,  $R_{11}$  –  $R_{13}$ , X and Y are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.



**ARYLMETHYL TRIAZOLO AND IMIDAZOPYRAZINES  
AS c-MET INHIBITORS**

**[0001]** This application claims the benefit of U.S. Provisional Application Serial No. 60/484,220, filed July 2, 2003, the disclosure of which is incorporated herein by reference in its entirety.

**BACKGROUND OF THE INVENTION**

**[0002]** The following is offered as background information only and is not admitted to be prior art to the present invention.

**[0003]** Protein kinases ("PKs") are enzymes that catalyze the phosphorylation of hydroxy groups on tyrosine, serine and threonine residues of proteins. The consequences of this seemingly simple activity are staggering; cell growth, differentiation and proliferation, *i.e.*, virtually all aspects of cell life in one way or another depend on PK activity. Furthermore, abnormal PK activity has been related to a host of disorders, ranging from relatively non-life threatening diseases such as psoriasis to extremely virulent diseases such as glioblastoma (brain cancer).

**[0004]** The PKs can be conveniently broken down into two classes, the protein tyrosine kinases (PTKs) and the serine-threonine kinases (STKs).

**[0005]** One of the prime aspects of PTK activity is their involvement with growth factor receptors. Growth factor receptors are cell-surface proteins. When bound by a growth factor ligand, growth factor receptors are converted to an active form which interacts with proteins on the inner surface of a cell membrane. This leads to phosphorylation on tyrosine residues of the receptor and other proteins and to the formation inside the cell of complexes with a variety of cytoplasmic signaling molecules that, in turn, effect numerous cellular responses such as cell division (proliferation), cell differentiation, cell growth, expression of metabolic effects to the extracellular microenvironment, *etc.* For a more complete discussion, see Schlessinger and Ullrich, *Neuron* 9:303-391 (1992), which is incorporated by reference, including any drawings, as if fully set forth herein.

**[0006]** Growth factor receptors with PTK activity are known as receptor tyrosine kinases ("RTKs"). They comprise a large family of transmembrane receptors with diverse biological activity. At present, at least nineteen (19) distinct subfamilies of RTKs have been identified. An example of these is the subfamily designated the "HER" RTKs, which include EGFR (epithelial growth factor receptor), HER2, HER3 and HER4. These RTKs consist of an extracellular glycosylated ligand binding domain, a transmembrane domain and an intracellular cytoplasmic catalytic domain that can phosphorylate tyrosine residues on proteins.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/20062

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 43/58, 43/60, 43/42, 43/40, 43/64, 43/52; A61K 31/495, 31/50, 31/44, 31/41, 31/415

US CL : 514/249, 300, 303, 338, 359, 394; 544/350; 546/117, 118, 268.4, 273.4; 548/257, 304.4

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/249, 300, 303, 338, 359, 394; 544/350; 546/117, 118, 268.4, 273.4; 548/257, 304.4

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
STN: Structure search in REGISTRY file, answers crossed in CAPLUS file.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 46-33957 (KAWANO et al) 10 May 1971 (10.05.1971), column 2, lines 1-10.	1, 10
X	US 4,804,658 (MANLEY et al) 14 February 1989 (14.02.1989), column 4, lines 34-55, Example 15.	1, 10
X	GRAY et al. Pyridylethylation of Skatole, Benzotriazole and Benzimidazole. Journal of Organic Chemistry. November 1960. Vol. 25, No. 11, pages 1939-1943, especially page 1940, compound IV.	2
X	LOVELETTE et al. Studies in Nonbridgehead Fused Nitrogen Heterocycles - Fused 1,2,3-Triazoles. Journal of Organic Chemistry. December 1972. Vol. 37, No. 25, pages 4124-4128, especially page 4125.	1, 5
X --- Y	KHANNA et al. Facile, Regioselective Syntheses of N-Alkylated 2,3-Diaminopyridines and Imidazo[4,5-b]pyridines. Journal of Organic Chemistry. February 1995, Vol. 60, No. 4, pages 960-965, especially 960 in "Introduction" and page 964, synthesis of 1-[(2-methoxyphenyl)methyl]-1H-imidazo[4,5-b]pyridine.	1, 4, 10 7, 8



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

02 November 2004 (02.11.2004)

Date of mailing of the international search report

01 DEC 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Zachary C. Tucker

Telephone No. (703) 308-0196

*J. Wehrhede*  
Far